These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33115272)

  • 1. Computationally Driven Discovery in Coagulation.
    Link KG; Stobb MT; Monroe DM; Fogelson AL; Neeves KB; Sindi SS; Leiderman K
    Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):79-86. PubMed ID: 33115272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mathematical model of coagulation under flow identifies factor V as a modifier of thrombin generation in hemophilia A.
    Link KG; Stobb MT; Sorrells MG; Bortot M; Ruegg K; Manco-Johnson MJ; Di Paola JA; Sindi SS; Fogelson AL; Leiderman K; Neeves KB
    J Thromb Haemost; 2020 Feb; 18(2):306-317. PubMed ID: 31562694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
    Girard TJ; Lasky NM; Grunz K; Broze GJ
    J Thromb Haemost; 2019 Jan; 17(1):149-156. PubMed ID: 30451376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma.
    Pieters J; Lindhout T; Hemker HC
    Blood; 1989 Aug; 74(3):1021-4. PubMed ID: 2502206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.
    Ninivaggi M; Dargaud Y; van Oerle R; de Laat B; Hemker HC; Lindhout T
    J Thromb Haemost; 2011 Aug; 9(8):1549-55. PubMed ID: 21605333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the activated protein C pathway in severe haemophilia A patients: The effects of thrombomodulin and a factor V-stabilizing fab.
    Brophy DF; Martin EJ; Mohammed BM; Barrett JC; Kuhn JG; Nolte ME; Wiinberg B; Holmberg HL; Lund J; Salbo R; Waters EK
    Haemophilia; 2017 Nov; 23(6):941-947. PubMed ID: 28750471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation.
    Brummel-Ziedins KE; Orfeo T; Gissel M; Mann KG; Rosendaal FR
    PLoS One; 2012; 7(1):e29178. PubMed ID: 22247769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulant effects of a synthetic peptide containing residues Thr-2253-Gln-2270 within factor VIII C2 domain that selectively inhibits factor Xa-catalysed factor VIII activation.
    Nogami K; Shima M; Nishiya K; Hosokawa K; Saenko EL; Giddings JC; Tanaka I; Yoshioka A
    Br J Haematol; 2002 Mar; 116(4):868-74. PubMed ID: 11886394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor.
    van 't Veer C; Hackeng TM; Delahaye C; Sixma JJ; Bouma BN
    Blood; 1994 Aug; 84(4):1132-42. PubMed ID: 8049429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN).
    van 't Veer C; Golden NJ; Kalafatis M; Simioni P; Bertina RM; Mann KG
    Blood; 1997 Oct; 90(8):3067-72. PubMed ID: 9376587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.
    Kamikubo Y; Mendolicchio GL; Zampolli A; Marchese P; Rothmeier AS; Orje JN; Gale AJ; Krishnaswamy S; Gruber A; Østergaard H; Petersen LC; Ruf W; Ruggeri ZM
    Blood; 2017 Oct; 130(14):1661-1670. PubMed ID: 28729433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
    Chowdary P
    Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies.
    Matsumoto T; Nogami K; Ogiwara K; Shima M
    Thromb Haemost; 2012 Feb; 107(2):288-301. PubMed ID: 22234708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptidomimetic inhibitors for activated protein C: implications for hemophilia management.
    Butenas S; Orfeo T; Kalafatis M; Mann KG
    J Thromb Haemost; 2006 Nov; 4(11):2411-6. PubMed ID: 17059471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.
    Damon AL; Scudder LE; Gnatenko DV; Sitaraman V; Hearing P; Jesty J; Bahou WF
    Thromb Haemost; 2008 Dec; 100(6):1111-22. PubMed ID: 19132238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein.
    Schuijt TJ; Bakhtiari K; Daffre S; Deponte K; Wielders SJ; Marquart JA; Hovius JW; van der Poll T; Fikrig E; Bunce MW; Camire RM; Nicolaes GA; Meijers JC; van 't Veer C
    Circulation; 2013 Jul; 128(3):254-66. PubMed ID: 23817575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
    Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J
    J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
    Waters EK; Genga RM; Schwartz MC; Nelson JA; Schaub RG; Olson KA; Kurz JC; McGinness KE
    Blood; 2011 May; 117(20):5514-22. PubMed ID: 21389323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.